How Clot Composition Influences Fibrinolysis in the Acute Phase of Stroke: A Proteomic Study of Cerebral Thrombi.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
Jul 2024
Historique:
medline: 24 6 2024
pubmed: 21 5 2024
entrez: 21 5 2024
Statut: ppublish

Résumé

The dramatic clinical improvement offered by mechanical thrombectomy raised questions about the relevance of prior intravenous thrombolysis in large-vessel occlusion strokes. Hence, studying intravenous thrombolysis susceptibility and its dependence on thrombus composition is crucial. We used an observational proteomic study of whole thrombi retrieved by mechanical thrombectomy to identify factors associated with fibrin content and fibrinolytic activity (FA). In 104 stroke patients, the thrombi proteome was established by mass spectrometry coupled to liquid chromatography. FA was estimated in clots both outside (FA FA Proteomics can offer new insights into the close relationship between thrombus composition and susceptibility to fibrinolysis, paving the way for new adjuvant therapies.

Sections du résumé

BACKGROUND UNASSIGNED
The dramatic clinical improvement offered by mechanical thrombectomy raised questions about the relevance of prior intravenous thrombolysis in large-vessel occlusion strokes. Hence, studying intravenous thrombolysis susceptibility and its dependence on thrombus composition is crucial. We used an observational proteomic study of whole thrombi retrieved by mechanical thrombectomy to identify factors associated with fibrin content and fibrinolytic activity (FA).
METHODS UNASSIGNED
In 104 stroke patients, the thrombi proteome was established by mass spectrometry coupled to liquid chromatography. FA was estimated in clots both outside (FA
RESULTS UNASSIGNED
FA
CONCLUSIONS UNASSIGNED
Proteomics can offer new insights into the close relationship between thrombus composition and susceptibility to fibrinolysis, paving the way for new adjuvant therapies.

Identifiants

pubmed: 38771990
doi: 10.1161/STROKEAHA.124.047156
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68
Fibrin 9001-31-4

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1818-1829

Investigateurs

Marie-Christine Alessi (MC)
Mickael Bobot (M)
Abdelmalek Brinet (A)
Sonia Dagnino (S)
Jean-Daniel Dehondt (JD)
Silvia Di Legge (SD)
Philippe Dory-Lautrec (P)
Cecile Dulau-Metras (C)
Pierre Durozard (P)
Basile Kerleroux (B)
Nadia Laksiri (N)
Barbara Leclercq (B)
Pierre Lehmann (P)
Ellen Magoncia (E)
Christine Manzac (C)
Ophelie Osman (O)
Roxane Peres (R)
Sandra Perez (S)
Caroline Rey (C)
Anthony Reyre (A)
Emmanuelle Robinet-Borgomano (E)
Salome Snyman (S)
Ljubica Svilar (L)
Catherine Tardivel (C)
Patricia Tourniaire (P)
Sivadji Vingadalassalom (S)

Auteurs

Emilie Doche (E)

Stroke Unit, University Hospital La Timone, AP-HM, Marseille, France (E.D., C.S., L.S.).
Centre de recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France (E.D., C.S., J.-C.M., L.S.).

Constance Sulowski (C)

Stroke Unit, University Hospital La Timone, AP-HM, Marseille, France (E.D., C.S., L.S.).
Centre de recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France (E.D., C.S., J.-C.M., L.S.).

Jean-Marie Guigonis (JM)

Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale, Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Côte d'Azur, School of Medicine, Nice, France (J.-M.G., F.G., S.L., T.P.).

Fanny Graslin (F)

Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale, Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Côte d'Azur, School of Medicine, Nice, France (J.-M.G., F.G., S.L., T.P.).
Centre Antoine Lacassagne, Nice, France (F.G.).

Barbara Casolla (B)

Stroke Unit, CHU Pasteur2, Nice, France (B.C.).

Jean-François Hak (JF)

Department of Neuroradiology, University Hospital La Timone, AP-HM, Marseille, France (J.-F.H., X.C., H.B.).

Xavier Carle (X)

Department of Neuroradiology, University Hospital La Timone, AP-HM, Marseille, France (J.-F.H., X.C., H.B.).

Hervé Brunel (H)

Department of Neuroradiology, University Hospital La Timone, AP-HM, Marseille, France (J.-F.H., X.C., H.B.).

Sabine Lindenthal (S)

Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale, Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Côte d'Azur, School of Medicine, Nice, France (J.-M.G., F.G., S.L., T.P.).

Jean-Charles Martin (JC)

Centre de recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France (E.D., C.S., J.-C.M., L.S.).

Thierry Pourcher (T)

Laboratory Transporter in Imaging and Radiotherapy in Oncology (TIRO), Direction de la Recherche Fondamentale, Institut des Sciences du Vivant Fréderic Joliot, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Côte d'Azur, School of Medicine, Nice, France (J.-M.G., F.G., S.L., T.P.).

Laurent Suissa (L)

Stroke Unit, University Hospital La Timone, AP-HM, Marseille, France (E.D., C.S., L.S.).
Centre de recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France (E.D., C.S., J.-C.M., L.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH